Price: 71.39 (9/4/21)

OS: 48M

Float: 36M

Cash: $400M (about 85 months worth)

Gene editing focused on heart disease.

vervetx.com/about-us 

Pipeline: https://www.vervetx.com/pipeline/

Note - nothing yet in human trials.

They went public at a favorable time for gene-editing focused companies.  They’re up about 150% from their first day at 30 in mid-June 2021.  Not much to report here, just been a general positive uptrend since then.

Market cap is $3.4B at the moment.

September 23
Updated Data from PCSK9 Gene Editing Program and LNP Delivery Approach to be Presented at TIDES 2021: Verve is scheduled to provide two presentations: (1) updated preclinical durability data from its lead program targeting PCSK9, in non-human primates (NHPs); and (2) new in vivo data highlighting its proprietary, internal lipid nanoparticle (LNP) delivery program (liver-targeting via incorporation of a novel GalNAc-targeting ligand) during oral sessions at the TIDES USA Oligonucleotide & Peptide Therapeutics Conference (TIDES 2021). Details of the presentations are as follows:
 
 Title: In vivo CRISPR Base Editing of PCSK9 Durably Lowers Cholesterol in Primates
Track: mRNA and Genome Editing TRACK: Genome Editing Advances from Preclinical to the Clinic
Date/Time: Thursday, September 23, 2021, 8:30 a.m. - 9:00 a.m. ET

Title: Targeted Delivery of Base Editors to Hepatocytes In Vivo
Track: Oligonucleotide CMC and Targeted Delivery TRACK: Targeted Delivery of Therapeutic Oligonucleotides
Date/Time: Thursday, September 23, 2021, 8:30 a.m. - 9:00 a.m. ET

I’ve got no position yet.  This one has been running hot, but it’s also got this data event this month.  It will likely keep going.  There might be another 15-20% on there, but I wouldn’t bet on more than that.  Then I think it will trade sideways until the IND in 2022.  Not much else known for it to run on until that point.

I think it’s almost at its short-term top.  Over $4B market cap is going to be a rich valuation for a gene editing stock not yet doing human trials.  However, the total addressable market is huge - heart disease - which costs the US healthcare system hundreds of billions each year.  I think it’s worth a short-term trade into the data event on September 23 and then swing by around at the IND filling.  Long-term this one should be golden for a buyout, if the science works out.